Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

as well as an annual capacity of over 1 billion oral VK2735 tablets. “These API (active pharmaceutical ingredient) and final finished product capacities are further expandable at Viking’s ...

as well as an annual capacity of over 1 billion oral VK2735 tablets. “These API (active pharmaceutical ingredient) and final finished product capacities are further expandable at Viking’s ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity. Under the ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 2.08 ...